Opus Genetics Secures $155 Million Financing Agreement to Support Clinical Development
Opus Genetics (NASDAQ:IRD) has secured up to $155 million in non-dilutive funding from Oberland Capital, along with a $5 million equity investment. The financing will extend the company's cash runway into 2029 and support pivotal studies for its gene therapy programs OPGx-LCA5 and OPGx-BEST1.
Topics: biotech financing agreement gene therapy NASDAQ